ImmuCell Corporation

NASDAQ: ICCC · Real-Time Price · USD
5.96
-0.76 (-11.31%)
At close: Aug 15, 2025, 1:10 PM

ImmuCell Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
26.49M 17.47M 18.57M 19.24M
Cost of Revenue
18.55M 13.08M 10.92M 10.59M
Gross Profit
7.94M 4.4M 7.65M 8.66M
Operating Income
-1.64M -5.75M -2.3M -2.2M
Interest Income
77.7K n/a 153.1K 18.81K
Pretax Income
-2.15M -5.77M -2.49M -69K
Net Income
-2.16M -5.77M -2.49M -78K
Selling & General & Admin
5.68M 5.22M 5.45M 4.23M
Research & Development
3.9M 4.39M 4.49M 4.17M
Other Expenses
n/a 527K n/a n/a
Operating Expenses
9.58M 10.14M 9.95M 8.4M
Interest Expense
568.73K n/a 348.54K 314.36K
Selling & Marketing Expenses
3.47M 3.09M 3.19M 2.5M
Cost & Expenses
28.13M 23.22M 20.87M 18.99M
Income Tax Expense
10.06K 4.63K 8K 9K
Shares Outstanding (Basic)
8.17M 7.7M 7.75M 7.59M
Shares Outstanding (Diluted)
8.17M 7.75M 7.75M 7.59M
EPS (Basic)
-0.26 -0.75 -0.32 -0.01
EPS (Diluted)
-0.26 -0.75 -0.32 -0.01
EBITDA
1.04M -2.5M 349.99K 2.72M
EBIT
-1.62M -5.22M -2.14M 237.39K
Depreciation & Amortization
2.69M 2.72M 2.49M 2.47M